Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 180 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: exemestane Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

NCT01963481
View directory record Official record
Conditions
Metastatic Beast Cancer
Interventions
Exemestane, Cyclophosphamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

NCT03300557
View directory record Official record
Conditions
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

NCT01594216
View directory record Official record
Conditions
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Interventions
Ruxolitinib, Exemestane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 16, 2026, 5:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

NCT01484041
View directory record Official record
Conditions
Breast Cancer
Interventions
Dovitinib, Aromatase Inhibitors
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 16, 2026, 5:43 PM EDT
Not listed Phase 2 Interventional

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

NCT02689921
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Letrozole, Anastrozole, Leuprolide Acetate, Pertuzumab, Trastuzumab
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Newnan, Georgia • Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

NCT01597193
View directory record Official record
Conditions
Breast Cancer
Interventions
enzalutamide, anastrozole, exemestane, fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
17
States / cities
Aurora, Colorado • Enfield, Connecticut • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 16, 2026, 5:43 PM EDT
Not listed No phase listed Observational

Aromatase Inhibitor Clinical Trial

NCT00228956
View directory record Official record
Conditions
Breast Cancer
Interventions
pharmacodynamic analysis
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
40 Years to 70 Years · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 16, 2026, 5:43 PM EDT
Recruiting Phase 3 Interventional

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

NCT06507618
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Tamoxifen, Letrozole, Anastrozole, or Exemestane
Drug
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
6
States / cities
New Haven, Connecticut • Charlottesville, Virginia • Culpeper, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

NCT02676986
View directory record Official record
Conditions
Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN
Interventions
Enzalutamide, Exemestane
Drug
Lead sponsor
Queen Mary University of London
Other
Eligibility
18 Years and older · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 16, 2026, 5:43 PM EDT
Terminated Phase 3 Interventional

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

NCT04869943
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 16, 2026, 5:43 PM EDT
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

NCT01594398
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions
entinostat, Erlotinib, Exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

NCT00676663
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
Interventions
entinostat, exemestane, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Greenbrae, California • La Jolla, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT00626106
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Metastatic Cancer
Interventions
AMG 479, Placebo
Drug
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
25
States / cities
Chandler, Arizona • Anaheim, California • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

NCT02392611
View directory record Official record
Conditions
Solid Tumors and Lymphomas
Interventions
Alobresib, Exemestane, Fulvestrant
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

NCT01446159
View directory record Official record
Conditions
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions
MEDI-573, Aromatase Inhibitor
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
34
States / cities
Scottsdale, Arizona • Bakersfield, California • Pleasant Hill, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

NCT01160211
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 16, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional

E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study

NCT07706374
View directory record Official record
Conditions
Poly Cystic Ovary Syndrome
Interventions
Exemestane 25 MG, Placebo, Exemestane 50 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

NCT00036270
View directory record Official record
Conditions
Breast Neoplasms
Interventions
exemestane (Aromasin), tamoxifen + exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older · Female only
Enrollment
9,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
179
States / cities
Bessemer, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 16, 2026, 5:43 PM EDT
Recruiting Phase 3 Interventional

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
57
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT03778931
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Standard of Care
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
104
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Fullerton, California + 84 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 16, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

NCT07071038
View directory record Official record
Conditions
Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
Interventions
Switch, Guideline Directed Intervention (GDI)
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 16, 2026, 5:43 PM EDT